[OC] Federal lobbying spend by all 17 TrumpRx pharmaceutical companies – Q1 2026 vs. Q4 2025, the quarter the program was being finalized
by MarkusGrant
[OC] Federal lobbying spend by all 17 TrumpRx pharmaceutical companies – Q1 2026 vs. Q4 2025, the quarter the program was being finalized
by MarkusGrant
1 Comment
Each bar shows the quarter-over-quarter change in federal lobbying expenditure for the 17 pharmaceutical manufacturers who joined TrumpRx, the Trump administration’s direct-to-consumer prescription discount program launched in February 2026.
Data: Senate LDA quarterly filings aggregated by OpenSecrets. Q1 2026 covers January through March 2026. Q4 2025 covers October through December 2025. All figures are client totals including in-house and outside lobbying firms.
15 of 17 companies increased lobbying in Q1 2026. Combined total: $50.1M, up $18.8M from Q4 2025. AstraZeneca led the surge at +258.2%.
Colors are each company’s primary corporate brand color.
Source: OpenSecrets, May 6, 2026 — https://www.opensecrets.org/news/2026/05/drug-companies-involved-in-trumprx-boosted-lobbying-by-23-ahead-of-programs-launch/